A relatively new and currently accepted diagnostic approach, The Mount Sinai Acute GvHD International Consortium algorithm probability (MAP), utilizes serum biomarkers ST2 and REG3α to determine damage to intestinal crypts in the context of GvHD [95]. The gene discussed is REG3A; the disease is graft versus host disease.